The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Shares of Sarepta Therapeutics SRPT surged more than 30% in after-market trading yesterday after the company announced a ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news ...

Sarepta stock catapulted Wednesday after the company announced a restructuring that includes 500 layoffs in the wake of two patient deaths.

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The biopharmaceutical company announced a strategic restructuring plan, laying off about 500 ...

Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures. What To Know: After the ...

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

US rare disease meds developer Sarepta Therapeutics late yesterday announced a strategic restructuring plan designed to ...

After the market close on Wednesday, Sarepta Therapeutics introduced a strategic restructuring plan that involves focusing on high-value, high-impact programs and supporting long-term financials.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...